The Reference Range Problem: Why "Normal" Is Not the Same as Optimal

There is a number on your lab report, and next to it, a range. If your number falls inside that range, the word "normal" appears — sometimes literally printed in that column — and the conversation moves on. No follow-up, no further inquiry, no curiosity about where inside that range you actually landed. The system has done its job. You have been cleared.

But "normal," in the clinical sense, has a precise and somewhat humbling definition. Reference ranges are typically constructed from the middle 95% of a tested population. They tell you, statistically, that you are not an outlier. What they do not tell you is whether you are well. They were never designed to answer that question.

This distinction — between the absence of disease and the presence of genuine vitality — sits at the heart of why hormone optimization is more nuanced than a single blood draw tends to reveal.

What the Population Average Obscures

Consider testosterone. In men, the commonly cited reference range spans a wide interval, often from roughly 300 to 1,000 nanograms per deciliter depending on the lab. A 38-year-old man whose level registers at 310 and a 38-year-old man whose level registers at 920 will both receive the same "normal" notation — despite the fact that their hormonal environments are profoundly different, and their lived experience of energy, body composition, mood, and cognitive sharpness is likely to reflect that difference in ways that accumulate quietly over years.

The biology here is worth sitting with. Testosterone levels in men decline at roughly 1–2% per year beginning around age 30. That rate of change is imperceptible in any given year. But compounded across a decade or two, many men find themselves at 50–60% of their young-adult values — still inside the reference range, technically unremarkable, but functionally a long way from where they once were. The range, built from a population that includes men across the full age spectrum, accommodates that decline rather than questioning it.

The goal was never to be average. It was to feel like yourself — at your best.

The Case of Women, Overlooked Longer

The conversation around testosterone has historically centered on men, which means it has historically left women underserved. But testosterone is physiologically active in women throughout their lives — influencing muscle synthesis, bone density, libido, mood, cognitive clarity, and cardiovascular function — and it declines in women just as it does in men, beginning earlier than most expect and accelerating through the perimenopause and postmenopausal years.

A 2022 review in the Journal of Personalized Medicine examined the evidence for testosterone therapy in women and found associations with improvements in sexual function, mood, energy, and lean body mass, noting that the clinical literature had advanced considerably even as awareness in mainstream practice lagged (Donovitz, 2022). More recently, a position statement from the Latin American Association of Gynecological Endocrinology addressed androgen therapy specifically in midlife and older women, reflecting growing consensus that this population represents a meaningful clinical opportunity that has historically gone underaddressed (Pilnik et al., 2025).

The implication is not that every woman needs testosterone therapy — it's that the question has often not been asked at all, because the reference range didn't flag a problem. When you build a range around a population that has broadly accepted hormonal decline as a natural feature of aging, the range simply encodes that acceptance. It doesn't challenge it.

What a More Complete Picture Requires

Thinking about hormone health in terms of optimization — rather than triage — means shifting the relevant question from is this person sick? to is this person functioning at their biological potential? That shift has practical consequences for how testing gets interpreted.

It means looking at where in a range someone lands, not just whether they cleared it. It means tracking changes over time rather than treating each data point as isolated. It means understanding the endocrine system as a network — where thyroid function influences cortisol, where cortisol affects insulin, where insulin affects testosterone, and where any disruption in one node propagates outward into others. And it means taking symptoms seriously as biological signals even when the numbers appear unremarkable at first glance.

The relevant variables, depending on the individual, might include:

• Total and free testosterone (the unbound fraction matters, as it's the biologically active portion)
• Estradiol, progesterone, and DHEA-S in women; estradiol in men receiving testosterone therapy
• Thyroid panel including free T3 and T4, not TSH alone
• Cortisol rhythm across the day, not a single-point measurement
• Growth hormone and IGF-1 as markers of repair and metabolic function

None of this is exotic. It's available. What it requires is a framing in which "normal" is understood as a floor, not a ceiling — and in which the distance between where someone is and where they could be is treated as information worth acting on.

The reference range is a useful tool. It was built to identify disease, and it does that reasonably well. But for the person who wants to feel genuinely well — not just disease-free — it's the beginning of the conversation, not the end of it. Knowing that your number falls within a wide population average tells you something. Knowing where you are relative to your own optimal, and understanding the direction you're trending over time, tells you something far more useful.